MoGRAA® Discovery Engine brings functional antibodies as new drug modality, to GPCR drug discovery, where low-molecular weight compounds have been dominated.
GPCR-targeted antibody from MoGRAA® Discovery Engine
NBHL has attractive GPCR-targeted antibody pipelines generated from MoGRAA® discovery engine. We are committed to research and development aiming for clinical application as soon as possible.
